systematic review of combination dmard therapy in ... review of combination dmard therapy in...
TRANSCRIPT
Systematic review of combination DMARD therapy
in rheumatoid arthritis
Beusekom I. van1, C. MacLean2, C.F. Allaart3, and F.C. Breedveld3.
October 2000
RE-2000.14
1) RAND Europe, Leiden, The Netherlands 2) RAND, UCLA school of medicine 3) Leiden University Medical Centre
63
CONTENTS List of abbreviations 66 Introduction 67 Systematic review of combination therapy in rheumatoid arthritis 71 Results 73 Summary of reviews on combination DMARD therapy 79 Appendix A: Weighted mean differences between DMARD and placebo 82 Appendix B: Adverse effects of selected disease modifying antirheumatic drugs (DMARDs) 84 References 86 Data abstraction tables 97 TABLES AND FIGURES: Table 1. Search terms used for electronic databases 71 Figure 1. Assessing the Jadad score 72 Figure 2. Literature retrieval flow chart 73 Table 2. Characteristics of eligible clinical trials of combination DMARD therapy in rheumatoid arthritis 75 Table 3. Characteristics and findings of published reviews on combination DMARD therapy in rheumatoid arthritis 80
65
List of abbreviations ACR American College of Rheumatology AUR Auranofin AZA Azathioprine Buc. Bucillamine CQ Chloroquine CRP C-reactive Protein CSA Cyclosporine DAS Disease Activity Score D-pen D-penicillamine DPS Dapsone Etan. Etanercept ESR Erythrocyte Sedimentation Rate GST Gold Sodium Thiomulate HCQ Hydroxychloroquine IFX Infliximab Leflu Leflunomide MP (Pulsed) Methylprednisolone MTX Methotrexate NR Not reported Plac. Placebo Predn. Prednisone/ prednisolone RAI Ritchie Articular Index RAM RAND Appropriateness Method RF Rheumatoid Factor SSA TNF
Sulphasalazine Tumor Necrosis Factor
66
INTRODUCTION
Rheumatoid arthritis is a systemic autoimmune disease of unknown aetiology. The most striking symptom is a chronic, symmetric synovitis of peripheral joints. Up to 70% of patients may ultimately develop bone erosions.1 Pain and swelling due to the inflammation, and later due to joint destruction, cause the patient limitation of movement and loss of functional abilities.
The therapeutic approach of rheumatoid arthritis (RA) aims to suppress the inflammatory process in order to reduce pain and disability, and prevent future joint destruction. Non-steroid anti-inflammatory drugs (NSAIDs) can be of value in reducing pain and stiffness, but are ineffective in suppressing the disease itself. Antirheumatic drugs, known as ‘second-line’ (being introduced in the past only after failure of ‘first-line’ NSAIDs), ‘slow-acting’ (because of the period of 6 to 8 weeks or sometimes more before the effects of the drug become noticeable), or ‘disease modifying’ (hence abbreviated as DMARDs) attenuate the disease itself through a variety of mechanisms. Reductions in pain,2-7 swelling,2-9 acute phase reactants,3,7,9 and the progression of bony erosions10-15 have been demonstrated with these agents. Additionally, these agents are associated with improvements in functional status.4 However, the efficacy of these agents has been neither large in magnitude nor sustained in duration. Furthermore, side effects among these agents are common and may be severe or life threatening.16-20 Few patients continue individual second line agents for longer than 2 or 3 years perhaps as a result of the limited efficacy and toxic side effects of these agents.21-24
Based in large part on the recognition that joint destruction may occur within the first years of disease onset,1,25 the approach to therapy for rheumatoid arthritis has become more aggressive over recent years. Patients are being treated earlier and with more potent (and toxic) agents now than previously. It is thought that early intervention may prevent joint erosions and may prevent the disease from becoming self-sustaining.10
The few studies that have evaluated the efficacy of early intervention support this hypothesis.26-28 In one study, early introduction of DMARDs was more effective in suppressing disease activity than treatment with NSAIDs alone.28 In another study, early relative to later initiation of DMARDs resulted in improved functional status and attenuated radiographic progression that persisted for 5 years.27,28
The rationale behind using therapies including combinations of DMARDs with potentially greater toxicities in RA, centres around the premise that these agents will retard structural damage and prevent disability more effectively than less toxic agents. Although the efficacy of most single agents compared to placebo in the treatment of RA has been demonstrated,2-9 the relative efficacy of various DMARDs compared to other DMARDs and the relative efficacy of different combinations of DMARDs is less well understood. This no doubt stems in large part from the large number of different agents available to treat RA. Given that treatment regimens may include DMARDs (antimalarials, azathioprine, cyclosporine, cyclophosphamide, gold, leflunomide, methotrexate, sulfasalazine), corticosteroids in higher or lower dosages and different
67
ways of administration, and biological agents (etanercept, infliximab), the number of possible combinations with two or more of these agents is quite large. The majority of these possible combinations have not been tested for effectiveness and safety. Some combinations that were tested in earlier years now appear to be farfetched or obsolete.
This review is part of a study for the Dutch Health Care Insurance Council [College voor zorgverzekeringen (CVZ)], which has called for a study to develop a generic method for examining combinations of medications. The goal of this study is to develop a method that can be used to determine where clinical research on pharmaceutical combinations is needed by evaluating the existing published evidence and clinical expertise about the use of these combinations. This generic method is to be pilot-tested by addressing the problem of prioritising clinical research on combination medications for rheumatoid arthritis (RA).
Regarding rheumatoid arthritis specifically, the CVZ realises that there is much uncertainty regarding the relative efficacy of different combinations of DMARD therapy and would like to help resolve this uncertainty by financing clinical trials to assess the efficacy of combination therapy. In order to determine which DMARD combinations should be studied in these clinical trials, the CVZ would like to understand what has been published as well as the opinions of experts about the efficacy of combination DMARD therapy. This project will synthesise the existing published literature and expert opinion on this topic by using the RAND Appropriateness Methods (RAM).
The RAM was originally developed over 15 years ago by a team of researchers at RAND and UCLA29,30 to assist in determining the extent of overuse of medical and surgical procedures (“inappropriate care”). The RAND Appropriateness Method (RAM) to determine "appropriate" care involves the following steps. When a topic has been selected, the first step of a study using the RAM is to perform a detailed literature review to synthesise the latest available scientific evidence on the procedure to be rated. The present document is the literature review for the appropriateness study on combination therapy with DMARDs. At the same time, a list of indications is produced in the form of a matrix that categorises patients who might present for the procedure in question in terms of their symptoms, past medical history and the results of relevant diagnostic tests.
The literature review and the list of indications are sent to the members of an expert panel. These panel members individually rate the appropriateness of using the procedures for each indication on a nine-point scale, ranging from extremely inappropriate (=1) to extremely appropriate (=9) for the patient described in the indication. The panel members assess the benefit-risk ratio for the "typical patient with specific characteristics receiving care delivered by the typical surgeon in the typical hospital."
After this first round of ratings, the panel members meet for one day under the leadership of a moderator. During this meeting, the panellists discuss their previous
68
ratings, focusing on areas of disagreement, and are given the opportunity to modify the original list of indications and/or definitions. After discussing each chapter of the list of indications, they re-rate each indication individually. The two-round process is focused on detecting consensus among the panel members. No attempt is made to force the panel to consensus.
Previous uses of the RAM have concentrated on determining the appropriateness or inappropriateness of treatment.30,31 Here, we instead are using the method to reveal uncertain, but promising combinations.
The following systematic review and summary of reviews on combination DMARD therapy in RA were performed as the first step of the RAM.
69
SYSTEMATIC REVIEW OF COMBINATION DMARD THERAPY IN RHEUMATOID ARTHRITIS Identification of Clinical Trials
We searched for clinical trials of combination therapy with DMARDs for the treatment of rheumatoid arthritis by using electronic searches of MEDLINE (1966- June 2000), EMBASE (1966 – June 2000) and the Cochrane Clinical Trials Registry (1965 –June 2000). The search terms used for each of these searches are described in table 1. Also, the bibliographies of major articles and reviews were screened for additional studies. Table 1. Search terms used for electronic databases. Database Search strategy Cochrane Clinical Trial Register “Arthritis, Rheumatoid” Embase “Combination therapy” and “Rheumatoid
Arthritis” and names of single DMARDs Medline “Combination therapy” and “Rheumatoid
Arthritis” and names of single DMARDs Inclusion Criteria
We included only randomised clinical trials that reported the efficacy of combinations of two or more DMARDs for the treatment of rheumatoid arthritis among patients 18 years of age or older. For this review, corticosteroids administered on a daily basis were considered DMARDs. Only studies that included at least one of the following outcome measures were included in this review: tender and/or swollen joint count, pain, physician or patient global assessment, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), radiographic outcome measures. Titles and abstracts for English and non-English language reports were reviewed to identify published studies. Articles in English, Dutch, German, French, Spanish and Danish were reviewed.
Data Extraction Two trained reviewers collected qualitative data including the methodological
attributes of the studies and characteristics of the study populations for each study using a standardised form. Disagreements were resolved by consensus. The data abstraction forms for each study have been included in this review.
Assessment of Methodological Attributes of Studies We assessed the methodological attributes of the studies by determining whether
or not descriptions of the following were present in each study: randomisation, appropriateness of randomisation, blinding, appropriateness of blinding, withdrawals and dropouts, and concealment of allocation. Each of these items has been validated as an indicator of methodological quality either individually32-34 or as part of a scale.32,35,36 We assigned an overall quality score to each study using the method developed by Jadad.35 This method assigns points based upon the description of specific methodological parameters (see figure 1). Studies are assigned one point each for describing
71
randomisation, blinding, and withdrawals and dropouts. An additional point each is added for describing an appropriate method of randomisation and an appropriate method of blinding; one point each is deducted if studies describe inappropriate methods of randomisation and inappropriate methods of blinding. The maximum score possible is 5. Studies with scores of three or more on this scale are considered high quality32,37,38 and report systematically different treatment effects in some clinical settings than studies with lower scores.32,37,38
Figure 1. Assessing the Jadad-score
Randomisation Was method of randomisation described? Yes: 1 point
Was the method of blinding appropriate? Yes: add 1 point No: subtract 1 point
Withdrawals and dropouts Was there a description of withdrawals and dropouts? Yes: 1 point
Jadad score
Was the method of randomisation appropriate? Yes: add 1 point No: subtract 1 point
Blinding Was the study double blind? Yes: 1 point
72
Assessment of characteristics of study population Because baseline characteristics of study subjects may affect response to therapy,
we abstracted data on the age, functional class, disease duration and prior use of DMARDs for all study arms in each study. Reviewers also qualitatively assessed whether meaningful differences in baseline characteristics of the study groups that could affect comparisons between arms were present in each study. RESULTS Trials Results from our literature search are detailed in figure 2. Figure 2. Literature retrieval flow chart.
Citations from electronic search: CCTR: 1905 Medline: 259 Embase: 105 Total: 2269 Abstracts: CCTR: 66 Medline: 71 Embase: 61 Total: 198 Met inclusion criteria
Check other reviews: Duplicates 9 _ +
Selected articles (inclusion criteria + other reviews – duplicates): 64
Accepted Rejected 28 35 (19 – no study 2 – language 5 – no RCT 9 – no combination therapy) Number of included studies: Total: 28
Our electronic search identified 2269 titles. Among these, 198 pertained to
combination therapy with DMARDs for RA. The abstract for each selected title was reviewed and from these 64 articles were selected for review. Among these, 62 (97%) were retrieved and 24 met our inclusion criteria. The search of bibliographies of major articles and reviews resulted in eight more articles to be retrieved. Four of these eight met our inclusion criteria. Among the articles rejected, 17 did not describe a clinical trial,
73
but rather were letters, comments or reviews; 2 did not meet our language requirement (one article in Russian and one in Japanese); 5 were not randomised; and 8 articles were not about combination therapy as we defined it.
The characteristics of the 28 studies included in this review are presented in table 2. Together, these studies assess the effects of 22 different combinations of DMARD therapies among 2819 patients. The majority (15) of the articles described studies on combinations with methotrexate, mostly combined with sulphasalazine, azathioprine, hydroxychloroquine or cyclosporine. The number of patients varied from 24 to 211 and the number of treatment groups from 2 to 7. Quality scores
The quality of the general methods of the studies assessed was generally good. The Jadad score was 3 or higher in 21 (79%) studies; concealment of allocation was described in 16 (57%) studies.
Characteristics of study populations
The average age of study participants ranged from 43.2 to 64. In most studies, the participants were aged 18-80. Disease duration ranged from 2.6 months to 11.5 years. Disease severity was described either in terms of functional class or the presence of rheumatoid factor in 8 and 12 studies respectively. Among studies that reported functional class, patients with Class I comprised 10% of the total subjects, Class II 73%, Class III 19% and Class IV 0.5%. Among studies reporting presence of rheumatoid factor, all reported that between 62 and 97% of the patients were rheumatoid factor positive. Whether or not DMARDs were used prior to study enrolment was described in 13 (46%) of the studies. In 11 studies, patients had been treated with DMARDs prior to study enrolment. In 18 studies, patients were randomly distributed over the different treatment arms, in 10 the procedure of allocation to treatment arms was less clear. In some cases there were some uncertainties about the comparability of the patients in the different arms (especially sex distribution and disease duration). In general, trials that compare newly started single drugs with newly started drug combinations offer a better insight than add-on studies, that compare the effect of adding another drug (or a placebo) to a drug that already failed.
74
Table 2. Characteristics of Eligible Clinical Trials of Combination DMARD therapy in Rheumatoid Arthritis Combination First author, Time of
assessment (weeks)
Year of publication ref.no
n patients (m/f)
Disease duration (yrs)
Disease severity
% withdrawals
Jadad score (1-5)
Concealment of allocation
CSA + CQ vs. CQ + plac.
Borne van den, 199870
0, 12, 24 88 (25/63) 3.8 vs. 5.6 months
RF: 68 vs 90%
25% vs 6%
5 Yes
D-pen + CQ vs. CQ + plac. vs. D-pen + plac.
Gibson, 198734 8, 16, 24, 36, 48
72 (35/47) 1 vs. 3 vs. 2
23% vs.5% vs. 7.6%
1 Not clear
D-pen. + MP vs. SSA + MP vs MP + plac.
Neumann, 198539
2, 4, 8, 12, 16, 20, 24
45 (16/29) 4 vs. 9 vs. 8
RAI: 21 Vs. 20 Vs. 22
26.6% vs. 46.6% vs. 86.6%
2 Not clear
SSA + HCQ vs. SSA + plac. vs. HCQ + plac.
Faarvang, 1993 71
4, 8, 12, 16, 20, 24
91 (35/56) 6.3 I: 71% II: 29%
26% vs. 41% vs. 29%
5 Yes
SSA+ MP vs. SSA + plac.
Ciconelli, 1996 72
8, 16, 24 38 (0/38) 6.9 vs. 6.1
II: 95% III: 5% vs. II:100%
25% vs. 22%
3-5 Yes
SSA + MTX + HCQ + predn. vs. SSA + AUR
Möttönen, 1999 73
12, 24, 36, 96 195 (74/121)
7.3 vs. 8.6 months
RF: 70% vs. 66%
24% vs. 22%
1 No
SSA + MTX + HCQ vs. SSA + HCQ + plac. vs. MTX + plac.+ plac.
O’Dell, 199640 12, 24, 36, 48, 60, 72, 84, 96
102 (31/71)
10 vs. 6 vs. 10
RF: 84% vs. 85% vs. 89%
22.5% vs. 60% vs. 66.6%
5 Yes
SSA + MTX + HCQ vs. MTX + HCQ vs. MTX + SSA
O’Dell, 2000 (abstract) 74
131 Yes
SSA+ MTX + predn. vs. SSA + plac.
Boers, 199710 16, 28, 40, 56 155 (64/91)
Median: 4 vs. 4 months
RF: 78% vs. 72%
9% vs. 29%
5 Yes
75
Combination First author, Time of
assessment (weeks)
Year of publication ref.no
n patients (m/f)
Disease duration (yrs)
Disease severity
% withdrawals
Jadad score (1-5)
Concealment of allocation
SSA + MTX vs. MTX
Haagsma, 199441
4, 8, 12, 16, 20, 24
40 (8/32) 4.7 vs. 5.3
RF: 77% vs. 72 %
9% vs. 0%
0 No
Dougados, 1999 75
0, 2, 4 the every 4 weeks until 52.
205 (54/151)
10.6 vs. 18.4 vs. 10.8 months
RF: 71% 62% 75%
25% vs. 21.7% vs. 30.9%
3/5 YesSSA + MTX vs. MTX + plac. vs. SSA + plac.
Haagsma, 199742
2,4, then every 4 weeks until 52
105 (37/68)
2.6 vs. 3.0 vs. 3.1 months
RF: 94% vs. 94% vs. 97%
16.7% vs. 5% vs. 35%
5 Yes
Willkens, 199236
6, 12, 18, 24 209 (44/165)
Median: 8 vs. 8 vs. 10
II: 84% vs. II: 80% vs. II: 78%
26% vs. 38% vs. 75%
5 Not clear
Willkens, 199543
6, 12, 18, 24, 48
209 (44/165)
Idem Idem 45% vs.64% vs. 33%
3-5 Not clear
MTX + AZA vs. AZA + plac. vs. MTX + plac.
Willkens, 199644
6, 12, 18, 24, 48
209 (44/165)
Idem Idem 45% vs.64% vs. 33%
3-5 Not clear
Williams, 199245
6, 12, 18, 24, 36, 48
335 (106/229)
6.2 vs. 4.6 vs. 5.3
(0-3): 2.0 vs. 1.85 vs. 1.94
37% vs. 40% vs. 34%
4 Not clearMTX + AUR vs. AUR + plac. vs. MTX + plac.
Lopez-Mendez, 199346
48 200 3 vs.2 vs. 3
III: 9 % III: 16 III: 20
N.A. 4 Yes
76
Combination First author, Time of
assessment (weeks)
Year of publication ref.no
n patients (m/f)
Disease duration (yrs)
Disease severity
% withdrawals
Jadad score (1-5)
Concealment of allocation
MTX + CSA vs. MTX + plac.
Tugwell, 199547 2, 4, 8, 12, 16, 20, 24
148 (41/107)
11.2 vs. 9.4
II: 91% III 8% vs. II: 82% III: 15%
25% vs. 16%
5 Yes
MTX + CQ vs. MTX + plc.
Ferraz, 199448 8, 16, 24 68 (11/57) 9.24 vs. 6.19
II: 88% III:12% Vs. II: 79% III:21%
21% vs. 21% 5 Yes
MTX + IFX vs. MTX + plac. vs. IFX + plac.
Maini, 199849 4, 8, 12, 16, 26
101 (73/28)
12.6 vs. 10.6 vs. 7.6
RF: 72.2 vs. 76.0 vs. 90.8
7% vs. 57% vs. 27%
5 Yes
MTX + cM-T412 Moreland, 199576
4, 8, 12, 24, 36, 48
64 (22/42) 8 vs. 10.9
II or III NR 3/4 Yes
HCQ + MTX vs. HCQ + plac.
Trnavsky, 199350
4, 12, 24 40 (9/31) II: 45% III: 55% vs. II: 50% III: 50%
5% vs. 0%
4 Not clear
HCQ + DPS vs. HCQ + plac. vs. DPS + plac
Haar, 199351 6, 12, 18, 24 80 (24/56) Median: 0.98 vs. 3.0 vs. 1.02
RF: 80% vs. 93% vs. 89%
56% vs. 17% vs. 17%
4 Yes
77
Combination First author, Time of
assessment (weeks)
Year of publication ref.no
n patients (m/f)
Disease duration (yrs)
Disease severity
% withdrawals
Jadad score (1-5)
Concealment of allocation
HCQ + D-pen vs. HCQ + plac. vs. D-pen + plac.
Bunch, 1984 77 24, 48, 72, 96 56 (17/39) 6.3 vs. 5.5 vs. 6.4
ARA*: II: 41% III: 59% Vs. II: 44% III: 44% Vs. II: 57% III: 38%
59% vs. 56% vs. 38%
5 Yes
Corkill, 1990 78 2, 4, 6, 8, 10, 12, 24
59 (21/38) 5.5 vs. 6.0
(1-4) 2.86 vs. 2.62
37% vs. 45%
3-5 YesGST + MP vs. GST + plac.
Van Gestel, 199552
12, 20, 44 40 (12/28) 21.5 vs. 29.5 months
RF: 80% vs. 85%
65% vs. 45%
5 Yes
GST + HCQ vs. GST + plac
Porter, 199353 26, 52 142 Median: 6 vs. 5
RAI: 17 vs. 12
14.8% vs. 18.5%
3 Yes
GST + HCQ vs. GST + plac.
Scott, 198938 8, 16, 24, 36, 48
101 (31/70)
2 vs. 2
Seropos 73% vs. 71%
48% vs. 35% 4 Not clear
GST + CSA Bendix, 199654 8, 16, 24 40 10.7 vs. 11.5
RF: 79% vs. 81%
15.7% vs. 5%
4 Yes
* ARA scale for disease activity: I-II-III
78
SUMMARY OF REVIEWS ON COMBINATION DMARD THERAPY
During the literature search, reviews about combination therapy were retrieved as well, in order to get an oversight of existing systematic overviews. The most important reviews are summarised in table 3.
79
Table 3. Characteristics and Findings of Published Reviews on Combination DMARD Therapy in Rheumatoid Arthritis Review Years covered Search strategy and inclusion criteria Number of
studies Conclusions Remarks
Boers, 1991 1956 - 1989 • Search in MEDLINE, Index Medicus, Excerpta Medica, and Science Citation Index, and search of bibliographies of retrieved articles
• Randomised trials and cohort studies - studies with evidence rated strong, moderate and weak are included
• Concurrent therapy with at least 2 antirheumatic drugs, compared with one single drug
• Outcome measure: severity of disease • Toxicity related to treatment is reported
7 studies (in total: 427 patients)
The available trials provide insufficient data to decide with confidence that any combination of antirheumatic drugs is to be preferred over a single drug.
Strict definition of active RA: 6 swollen joints plus 2 of 3 of the following criteria: - 9 or more tender
joints - morning stiffness 45
minutes - ESR 28 mm/h
Borigini, 1995 1984 - 1994 No description of search strategy and inclusion criteria
14 studies (in total: 1547 patients)
Lack of well-designed, large, long-term, control-led clinical trials.
Felson, 1994 ? - December 1992
• MEDLINE, bibliographic searches, hand searches of 5 international rheumatology journals, and abstracts of ACR-meetings
• Randomized clinical trials • Patients > 18 years of age • Two full-dose second-line drugs started
concurrently • Drugs and minimal dose: AUR (6 mg/day),
HCQ (200 mg/day), CQ (250 mg/day), i.m. gold (50 mg/week), MTX (7.5 mg/week), AZA (1 mg/kg/day), SZA (2 mg/day), D-pen (500 mg/day)
• Numerical data on start and end values must be provided
• Comparison with one of the single second-line drugs listed above at full therapeutic
5 studies (in total 749 entering patients and 516 completing patients)
Combination therapy does not offer a substantial improvement in efficacy, but does have higher toxicity than single drug therapy.
80
dose Review Years covered Search strategy and inclusion criteria Number of
studies Conclusions Remarks
Verhoeven, 1998
1992 - 1997 • MEDLINE search and search of bibliographies of the retrieved articles.
• English, French, German, Dutch • Randomized studies - studies with evidence
rated as strong or moderate are included • Comparison with a one-type single
DMARD control group
20 studies (10 on parallel treatment, 6 on step-up strategy, and 4 on step-down strategy); in total 1952 patients
In early RA patients, step-down bridge therapy that includes corticosteroids leads to much enhanced efficacy at acceptable or low toxicity. The effects on joint damage may be persistent, but the symptomatic effects are probably dependent on continued corticosteroid dosing. In late patients, cyclosporine improves a suboptimal clinical response to methotrexate, and the triple combination of methotrexate, sulphasalazine, and hydroxychloroquine appears clinically better than the components. Other combinations are either untested, tested at low sample, or show negative interaction.
Scott, 1999 1966 - 1990 • MEDLINE search • Randomised controlled trials, non-
randomised studies of parallel group design, observational open studies, retrospective reviews.
11 studies (in total: 486 patients)
The balance of evidence in 1990 suggested that combination therapy had a modest advantage. However, the trials were too small to detect its true value, and the combinations used were not ideal.
81
Appendix A: Weighted mean differences between DMARD and placebo (95% confidence interval) for outcomes among patients with rheumatoid arthritis
Outcome Drug
Tender Joint Count
Swollen Joint Count
Pain** PhysicianGlobal Assessment
Patient Global Assessment
Functional Assessment*
Acute Phase reactant (ESR)
Penicillamine (<500 mg/d)
-6.00 (-11.36, -0.64)
-2.00 (-5.96, 1.96)
-11.00 (-23.19, 1.19)
-0.42 (-0.72, -0.12)
-0.36 (-0.65, -0.07)
. -8.00 (-22.01, 6.01)
Penicillamine (500 - 1000mg/d)
-6.61 (-11.37, -1.85)
-5.00 (-9.11, -0.89)
-0.63 (-1.00, -0.26)
-0.77 (-0.98, -0.56)
-0.56 (-0.86, -0.26)
. -10.65 (-20.89, -0.41)
Penicillamine (>1000 mg/d)
-8.90 (-16.63, -1.16)
. -0.61 (-0.91, -0.31)
-1.07 (-1.36, -0.78)
0.00 (0.00, 0.00)
13.90 (-37.03, 9.23)
-14.39 (-23.21, -5.58)
Sulphasalazine -2.448(-4.15, -0.74)
-2.379 (-3.73, -1.03)
-8.71 (-14.80, -2.62)
-0.16 (-0.38, 0.01)
-0.23 (-0.46, 0.00)
0.00 (0.00, 0.00)
-17.58 (-21.93, -13.23)
Methotrexate -17.85(-23.97, -11.73)
-7.31 (-10.44, -4.18)
-3.00 (-4.07, -1.93)
-1.05 (-1.31, -0.80)
-0.91 (-1.20, -0.63)
-0.48 (-0.58, -0.38)
-8.95 (-18.17, 0.27)
Cyclosporine
-8.20(-12.64, -3.76)
-3.19 (-4.29, -2.10)
-1.45 (-2.32, -0.57)
0.34 (-0.02, 0.69)
0.08 (-0.25, 0.41)
. .
Cyclophosphamide
-9.62(-17.72, -1.53)
-6.88 (-12.04, -1.71)
. . . .-11.61 (-25.72, 2.51)
82
Azathioprine
-3.08(-5.24, -0.93)
-18.00 (-24.76, -11.24)
-25.09 (-42.11, -8.07)
. .-0.24 (-0.79, 0.31)
-12.94 (-33.94, 8.05)
Antimalarials -2.57(-3.78, -1.36)
-3.71 (-4.86, -2.57)
-0.45 (-0.72, -0.18)
-0.39 (-0.57, -0.21)
-0.34 (-0.53, -0.15)
-0.06 (-0.29, 0.17)
-6.38 (-8.51, -4.24)
Injectable gold .
-4.58 (-6.50, -2.65) .
-0.34 (-0.48, -0.20)
-0.48 (-0.77, -0.19)
. -13.16 (-18.14, -8.18)
*Functional assessment = Steinbrocker etc. **Pain = VAS
83
Appendix B. Adverse affects of selected disease modifying antirheumatic drugs (DMARDs).
Drug name Adverse effects % Citation
Hydroxychloroquine Retinal toxicity Sulphasalazine Rash (and fever)
Myelosuppression Gastrointestinal intolerance
1-5 1-5 33
55 55 56
Gold (Auranofin)
Rash Stomatitis Myelosuppression Thrombocytopenia Proteinuria Diarrhea
18-26 60-80
<1 1-3 <1 >10
56 57
58-60 57 61 62
Methotrexate Gastrointestinal intolerance Rash Stomatitis Alopecia Myelosuppression Hepatotoxicity Pneumonitis
2.5 1-2 6-10 <1 <5 <1 3-5
63 64
64,65 65 63 66 63
Azathioprine Leukopenia Hepatotoxicity Early flu-like illness with fever Anemia Nausea Thrombocytopenia Pancytopenia Alopecia
2.5-4.5 3-10
8 0-1.5
9.6-15.2 0-2.0 0-0.5
1.5-2.0
67 56 67 67 67 67 67 67
Cyclosporine Nephrotoxicity Anemia Thrombocytopenia Hypertension
25-80 <2 <2 11
56 56 56 56
84
Appendix B (continued). Adverse affects of selected disease modifying antirheumatic drugs (DMARDs).
Drug name Side effects % Citation
Leflunomide Transaminitis Gastrointestinal intolerance Teratogenicity (category x) Rash Alopecia
6 15 8
1-7
56 56 56 56 56
Etanercept Theoretic risk of infection Injection site reactions Upper respiratory symptoms
37
Up to 45
56 56
D-penicillamine Rash Stomatitis Dysgeusia Proteinuria Myelosuppression Secondary autoimmune disease Thrombocytopenia
Up to 50 >10 >10 <1 <1 <1 5
56 68 68 68 68 68 69
Cyclophosphamide Myelosuppression Myeloproliferative disorders Infection Alopecia Hepatotoxicity
40-60
56
Infliximab Anaphylaxis Infection
85
References
1. Van Der Heijde D. Joint erosions and patients with early rheumatoid arthritis. Br
J Rheum. 1995;34:74-78.
2. Suarez-Almazor M, Spooner C , and Belseck E. Penicillamine for rheumatoid
arthritis (Cochrane Review). In: The Cochrane Library. 1999;4:Update Software.
3. Suarez-Almazor M, Belseck E, Shea B, Wells G , and Tugwell P. Sulfasalazine
for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library.
1999;4:Update Software.
4. Suarez-Almazor M, Belseck E, Shea B, Wells G , and Tugwell P. Methotrexate
for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library.
1999;4:Update Software.
5. Wells G, Haguenauer D, Shea B et al. Cyclosporine for rheumatoid arthritis
(Cochrane Review). In: The Cochrane Library. 1999;4:Update Software.
6. Suarez-Almazor M, Spooner C , and Belseck E. Azathioprine for rheumatoid
arthritis (Cochrane Review). In: The Cochrane Library. 1999;4:Update Software.
7. Suarez-Almazor M, Belseck E, Shea B, Homik J , and Wells GTP. Antimalarials
for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library.
1994;4:Update Software.
8. Suarez-Almazor M, Belseck E, Shea B, Wells G , and Tugwell P.
Cyclophosphamide for rheumatoid arthritis (Cochrane Review). In: The
86
Cochrane Library. 1999;4:Update Software.
9. Clark P, Tugwell P, Bennet K et al. Injectable gold for rhuematoid arthritis
(Cochrane Review). In: The Cochrane Library. 1999;4:Update Software.
10. Boers M, Verhoeven A, Markusse H et al. Randomised comparison of combined
step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine
alone in early rheumatoid arthritis. Lancet. 1997;350:309-318.
11. Bresnihan B, Alvaro-Garcia J, Cobby M et al. Treatment of Rheumatoid Arthritis
with recombinant human interleukin-1 receptor anatagonist. Arthritis Rheum.
1998;41:2196-2204.
12. Forre O, and the Norwegian Arthritis Study Group. Radiologic evidence of
disease modification in rheumatoid arthritis patients treated with cyclosporine.
Arthritis Rheum. 1994;37:1506-1512.
13. Kirwan J, and The arthritis and rheumatism council, low-dose glucocorticoid
study group. The effect of glucocorticoids on joint destruction in rheumatoid
arthritis . N Engl J Med. 1995;333:142-146.
14. Smolen J, Kalden J, Scott D et al. Efficacy and safety of leflunomide compared
with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind,
randomised, multicentre trial. Lancet. 1999;353:259-266.
15. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with
Leflunomide compared with placebo and Methotrexate. Arch Intern Med.
87
1999;159:2542-2550.
16. Lockie L, and Smith D. Forty-seven years experience with gold therapy in 1019
RA patients. Semin Arthritis Rheum. 1985;14:238-246.
17. Gerber R, and Paulus H. Gold therapy . Rheum Dis Clin North Am. 1975;1:307-
318.
18. Weinblatt M. Toxicity of low dose methotrexate in rheumatoid arthritis. J
Rheum. 1985;12:35-39.
19. Singh G, Fries J, Spitz P , and Williams C. Toxic effects of azathioprine in RA: a
national post-marketing perspective. Arthritis Rheum. 1989;32:837-843.
20. Cash J, and Klippel J. Second line drug therapy for rheumatoid arthritis. N Engl J
Med. 1994;330:1368-1375.
21. Pincus T, and Callahan L. The "side effects" of rheumatoid arthritis: Joint
destruction, disability and early mortality. Br J Rheum. 1993;32:28-37.
22. Pincus T, Marcum S , and Callahan L. Longterm drug therapy for rheumatoid
arthritis in seven rheumatology private practices: II Second line drugs and
prednisone. J Rheumatol. 1992;19:1885-94.
23. Pincus T, The case for early intervention in rheumatoid arthritis. J Autoimmun.
1992;5:209-226.
24. Wolfe F, Hawley D , and Cathey M. Termination of slow acting antirheumatic
therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017
88
consecutive starts. J Rheumatol. 1990;17:994-1002.
25. Van der Heijde D, Van Leeuwen M, Van Riel P et al. Biannual radiographic
assessments of hands and feet in a three year prospective follow-up of patients
with early rheumatoid arthritis. Arthritis Rheum. 1992;35:
26. Van der Heijde A, Jacobs J, Bijlsma J et al. The effectiveness of early treatment
with ‘second-line’ antirheumatic drugs. A randomized controlled trial. Ann Intern
Med. 1996;124:
27. Egmose C et al. Patients with rheumatoid arthritis benefit from early second line
therapy: 5 year follow-up of a prospective double blind placebo controlled study.
J Rheumatol. 1995;22:2208-2213.
28. Borg G, Allander E, Lund B et al. Auranofin improves outcome in early
rheumatoid arthritis. Results from a 2-year double blind, placebo controlled
study. J Rheumatol. 1988;15:1747-1754.
29. Park R, Fink A, Brook R et al. Physician ratings of appropriate indications for six
medical and surgical procedures. Am J Pub Health. 1986;76:766-772.
30. Brook R. The RAND/UCLA Appropriateness Method . Methodology
Perspectives . 1994;Rockville, Maryland: Public Health Service, U.S. Department
of Health and Human Services, AHCPR Publication No. 95-0009, pp. 59-70.
31. Fitch K, Bernstein S, Aguilar M et al. The RAND/UCLA Appropriateness
Method. User’s Manual. Santa Monica;2000: MR-1269.
89
32. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials
affect estimates of intervention efficacy reported in meta-analyses? Lancet.
1998;352:609-613.
33. Schulz K, Chalmers I, Hayes R et al. Dimensions of methodological quality
associated with estimates of treatment effects in controlled trials. JAMA.
1995;273:408-412.
34. Gibson T, Emery P, Armstrong A, Crisp A , and Panayi G. Combined d-
penicillamine and chloroquine treatment of rheumatoid arthritis - a comparative
study . Br J Rheum. 1987;26:279-284.
35. Jadad A, Moore A, Carrol D et al. Assessing the quality of reports of randomized
clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12.
36. Willkens R, Urowitz M, Stablein D et al. Comparison of azathioprine,
methotrexate, and the combination of both in the treatment of rheumatoid
arthritis: A controlled clinical trial. A&R. 1992;35:849-856.
37. Kahn K, Daya S , and Jadad A. The importance of quality of primary studies in
producing unbiased systematic reviews. Arch Intern Med. 1996;156:661-666.
38. Scott D, Dawes P, Tunn E et al. Combination therapy with gold and
hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-
controlled study. Br J Rheum. 1989;28:128-133.
39. Neumann V, Hopkins R, Dixon J et al. Combination therapy with pulsed
90
methylprednisolone in rheumatoid arthritis. Ann Rheum Dis. 1985;44:747-751.
40. O'Dell J, Haire C, Erikson N et al. Treatment of rheumatoid arthritis with
methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of
all three medications. NEJM. 1996;334:1287-1291.
41. Haagsma C, Van Riel C, De Rooij D et al. Combination of methotrexate and
sulphasalazine vs methotrexate alone: a randomized open clinical trial in
rheumatoid arthritis pateints resistant to sulphasalazine therapy. Br J Rheum.
1994;33:1049-1055.
42. Haagsma C, Van Riel P, De Jong A , and Van de Putte L. Combination of
sulphasalazine and methotrexate versus the single components in early
rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical
trial. Br J Rheum. 1997;36:1082-1088.
43. Willkens R, Sharp J, Stablein D, Marks C , and Wortmann R. Comparison of
azithioprine, methotrexate, and the combination of the two in the treatment of
rheumatoid arthritis: a forty-eight-week controlled clinical trial with radiologic
outcome assessment. A&R. 1995;38:1799-1806.
44. Willkens R, and Stablein D. Combination treatment of rheumatoid arthritis using
azathioprine and methotrexate: a 48 week controlled clinical trial . J Rheum.
1996;23:64-68.
45. Williams H, Ward J, Reading J et al. Comparison of auranofin, methotrexate, and
the combination of both in the treatment of rheumatoid arthritis: a controlled
91
clinical trial. A&R. 1992;35:259-269.
46. Lopez-Mendez A, Daniel W, Reading J, Ward J , and Alarcon G. Radiographic
assessment of disease progression in rheumatoid arthritis patients enrolled in the
cooperative systematic studies of the rheumatic diseases program randomized
clinical trial of methotrexate, auranofin, or a combination of the two. A&R.
1993;36:1364-1369.
47. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and
methotrexate in severe rheumatoid arthritis. NEJM. 1995;333:138-141.
48. Ferraz M, Pinheiro GHM, Albuquerque E et al. Combination therapy with
methotrexate and chloroquine in rheumatoid arthritis: A multicenter randomized
placebo-controlled trial. Scand J Rheumatol. 1994;23:231-236.
49. Maini R, Breedveld F, Kalden J et al. Therapeutic efficacy of multiple
intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody
combined with low-dose weekly methotrexate in rheumatoid arthritis. A&R.
1998;41:1552-1563.
50. Trnavsky K, Gatterova J, Linduskova M , and Peliskova Z. Combination therapy
with hydroxychloroquine and methotrexate in rheumatoid arthritis. Zeit fur
Rheum. 1993;52:292-296.
51. Haar D, Solvkajaer M, Unger B et al. A double-blind comparative study of
hydroxychloroquine and dapsone, alone and in combination, in rheumatoid
arthritis. 1993;22:113-118.
92
52. Van Gestel A, Laan R, Haagsma C, Van De Putte L , and Van Riel P. Oral
steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral
gold. A randomized double-blind placebo-controlled trial. Br J Rheum.
1995;34:347-351.
53. Porter D, Capell H , and Hunter J. Combination therapy in rheumatoid arthritis -
no benefit of addition of hydroxychloroquine to patients with a suboptimal
response to intramuscular gold therapy. J Rheum. 1993;20:645-9.
54. Bendix G and Bjelle A. Adding low-dose cyclosporin a to parenteral gold therapy
in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheum.
1996;35:1142-1149.
55. Day R. Sulfasalazine . Textbook of Rheumatology. 1993;4th Ed.:Philadelphia,
WB Saunders.
56. Micromedex Inc. Micromedex Healthcare Series. 2000.
57. Gordon D. Gold compounds in the rheumatic diseases. in textbook of
rheumatology 4th ed. 1993;Philadelphia, WB Saunders.
58. Lockie L and Smith D. Forty-seven years experience with gold therapy in 1019
RA patients. Semin Arthritis Rheum. 1985;14:238-246.
59. Davis P and Hughes G. Significance of eosinophilia during gold therapy.
Arthritis & Rheumatism. 1974;17:964-968.
60. Gerber R and Paulus H. Gold therapy . Rheum Dis Clin North Am. 1975;1:307-
93
318.
61. Kelley, W, Harris, E, Ruddy, S, and Sledge, C. Volume 1. Textbook of
Rheumatology. 5th edition Philadelphia, PA; W.B. Saunders Company. 97 (Ch.
48).
62. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.
Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis &
Rheumatism. 1996;39:723-731.
63. Weinblatt M. Methotrexate, in textbook of rheumatology. 4th ed. 1993;Kelley
WN, Harris ED Jr., Ruddy S, Sledge CB eds.
64. Klippel, J and Dieppe, P. Rheumatology. London; Times Mirror International
Publishers Limited. 94 (8.13.3).
65. Weinblatt M. Toxicity of low dose methotrexate in RA. J Rheum. 1985;12:35-39.
66. Kelley, W, Harris, E, Ruddy, S, and Sledge, C. Volume 1. Textbook of
Rheumatology. 5th edition Philadelphia, PA; W.B. Saunders Company. 97 (Ch.
49).
67. Singh G, Fries J, Spitz P, and Williams C. Toxic effects of azathioprine in RA: a
national post-marketing perspective. Arthritis & Rheumatism. 1989;32:837-843.
68. Jaffe I. Penicillamine . in textbook of rheumatology 4th ed. 1993.
69. Cash J and Klippel J. Second line drug therapy for RA. New England J of Med.
1994;330:1368-1375.
94
70. Van den Borne, B.E.E.M., R.B.M. Landewé, et al. Combination therapy in recent
onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose
cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998; 25:1493-
8.
71. Faarvang K.L, Egsmose C. et al. Hydroxychloroquine and sulphasalazine alone and
in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis
1993; 52:711-715.
72. Ciconelli R.M., Ferraz M.B, Visioni R.A., Oliveira L.M. and E. Atra. A randomized
double-blind controlled trial of sulphasalazine combined with pulses of
methylprednisolone or placebo in the treatment of rheumatoid arthritis. Br.J. of Rheum.
1996; 35: 150-154.
73. Möttönen T, Hannonen P. et al. Comparison of combination therapy with single-drug
therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999; 353: 1568-1572.
74. O’Dell J, Lelf R, et al. Methotrexate (M)- Hydroxychloroquine (H)- Sulfasalazine (S)
versus M-H of M-S for rheumatoid arthritis (RA): results of a double blind study. 2000.
Abstract submitted for ACR conference November 14, 1999.
75. Dougados M, Combe B et al. Combination therapy in early rheumatoid arthritis: a
randomised, controlled, double blind 52 week clinical trial of sulphasalazine and
methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-225.
76. Moreland L.W, Pratt, P.W, et.al. Double-blind, placebo-controlled multicenter trial
using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients
receiving concomitant methotrexate. Arthritis & Rheumatism 1995; 38 vol 11: 1581-
1588.
95
77. Bunch Th.W, O’Duffy J.D., Tompkins R.B, and W.M. O’Fallon. Controlled trial of
hydroxychloroquine and D-penicillamine singly and in combination in the treatment of
rheuamtoid arthritis. Arthritis & rheumatism 1984; 27: 267-276.
78. Corkill M.M, B.W. kirkham, I.C. Chikanza, T. Gibson and G.S. Panayi.
Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid
arthritis: a 24-week randomized controlled trial. Br.J. of Rheum 1990; 29: 274-279.
96